CG Oncology (CGON) Equity Ratio (2023 - 2026)

CG Oncology (CGON) has 4 years of Equity Ratio data on file, last reported at 0.96 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 0.63% year-over-year to 0.96; the trailing twelve-month figure through Mar 2026 stood at 0.96 (down 0.63% YoY), and the FY2025 full-year result was 0.95, down 2.15% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.96, up from 0.95 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.98 in Q1 2024 and bottomed at 0.62 in Q4 2023.
• The 4-year median for Equity Ratio is 0.96 (2025), against an average of 0.81.
• The widest annual swing landed in 2024, when Equity Ratio soared 257.31%; it then decreased 3.04% in 2025.
• A 4-year view of Equity Ratio shows it stood at 0.62 in 2023, then jumped by 257.31% to 0.97 in 2024, then dropped by 2.15% to 0.95 in 2025, then increased by 1.15% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.95 (Q4 2025), and 0.94 (Q3 2025), per Business Quant data.

Peer Comparison